home > ict > winter 2020 > removing barriers for paediatric patients in clinical trials
International Clinical Trials

Removing Barriers for Paediatric Patients in Clinical Trials

Designed by Katemangostar / Freepik

As scientific breakthroughs in healthcare advance, our ability to discover and diagnose diseases earlier has renewed the need for paediatric research. However, there has been a growing tension between the need to license medication, strict regulations, and the recognised unprofitability of conducting trials in the paediatric population.

A major consideration in paediatric trials involves balancing the rights, safety, and well-being of children while meeting financial requirements to enable the production of safe, licensed medication. Perceived challenges in striking this balance may be a deterrent for some pharmaceutical companies.

Some of the key challenges include a lack of paediatric trials, leading to fewer licensed medications for children, misconceptions and mistrust participants may have in research, which may hinder participation in clinical trials, and how the industry may influence paediatric research through community education, with a hope that children will not be left behind as healthcare research continues to progress.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the author

Evelyn Kamau is the Global Head of Nursing at the MRN and has over 20 years’ nursing experience. Evelyn has worked in critical care, haemodialysis and neurology centres both in the UK and her native country Kenya. Evelyn has been a lecturer for both undergraduate and postgraduate nursing students, a position that led her to the neurosurgery department at Cambridge University, where she was involved in pioneering research in the understanding and management of disorders of consciousness. She left Cambridge University to manage community-based trials at the MRN in 2016.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Winners of the 2021 CPhI Pharma Awards have now been announced

Milan, 10 November 2021: CPhI Worldwide announces the winners of the 18th edition of the CPhI Pharma Awards, hosted live in Milan, with winners spanning some 10 distinct categories. The Awards seek to recognise ‘Excellence in Pharma’ , assessing entries from the industry leading companies and individuals.
More info >>

White Papers

Device Develop for Combo Products


Combination products are defined as therapeutics combining two or more products (drug/device, biologics/device, biologics/drugs or drug/device/biologics), regulated and sold as a single unit. As these pharmaceutical and biological therapies and treatments have evolved, so has the need to develop appropriate delivery mechanisms for these applications. When developing a combination product, there are many things that need to be considered – the critical relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding ‘user’ needs, determining product requirements, as well as, device manufacturing variation.
More info >>




©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement